Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression

Cell Death and Differentiation

Volumn 14, Issue 10, 2007, Pages 1780-1791

  Phillips, D C ^a   Hunt, J T ^a   Moneypenny, C G ^a   Maclean, K H ^a   McKenzie, P P ^a   Harris, L C ^a   Houghton, J A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOHEXIMIDE; PROTEASOME; PROTEIN BCL 2; PROTEIN MDM2; SMALL INTERFERING RNA; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RHABDOMYOSARCOMA; CELL CYCLE; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MURINAE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CERAMIDES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MDM2; RHABDOMYOSARCOMA; RNA, SMALL INTERFERING;

EID: 34548776512     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402198     Document Type: Article

References (44)

1. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4: 604-616.
2. Goni FM, Alonso A. Biophysics of sphingolipids I. Membrane properties of sphingosine. Ceramides and other simple sphingolipids. Biochim Biophys Acta 2006; 1758: 1902-1921.
3. Phillips DC, Griffiths HR. Ceramide induces a loss in cytosolic peroxide levels in mononuclear cells. Biochem J 2003; 375: 567-579.
4. Lee JY, Bielawska AE, Obeid LM. Regulation of cyclin-dependent kinase 2 activity by ceramide. Exp Cell Res 2000; 261: 303-311.
5. Altura BM, Gebrewold A, Zheng T, Altura BT. Sphingomyelinase and ceramide analogs induce vasoconstriction and leukocyte-endothelial interactions in cerebral venules in the intact rat brain: Insight into mechanisms and possible relation to brain injury and stroke. Brain Res Bull 2002; 58: 271-278.
6. Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 2005; 65: 11447-11458.
7. Daido S, Kanzawa T, Yamamoto A, Takeuchi H, Kondo Y, Kondo S. Pivotal role of the cell death factor BNIP3 in caramide-induced autophagic cell death in malignant glioma cells. Cancer Res 2004; 64: 4286-4293.
8. Phillips DC, Allen K, Griffiths HR. Synthetic ceramides induce growth arrest or apoptosis by altering cellular redox status. Arch Biochem Biophys 2002; 407: 15-24.
9. Lee JY, Leonhardt LG, Obeid LM. Cell-cycle-dependent changes in ceramide levels preceding retinoblastoma protein dephosphorylation in G2/M. Biochem J 1998; 334 (Part 2): 457-461.
10. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
11. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
12. Jin Y, Lee H, Zeng SX, Dai MS, Lu H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 2003; 22: 6365-6377.
13. Liu CW, Corboy MJ, DeMartino GN, Thomas PJ. Endoproteolytic activity of the proteasome. Science 2003; 299: 408-411.
14. Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 2000; 5: 403-410.
15. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 2004; 279: 16000-16006.
16. Corvi R, Savelyeva L, Breit S, Wenzel A, Handgretinger R, Barak J et al. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 1995; 10: 1081-1086.
17. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
18. Oliner JD, Kinzler KW, Meltzer PS, George DI, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
19. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-2739.
20. Bartel F, Taylor AC, Taubert H, Harris LC. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol Res. 2000; 12: 451-457.
21. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 2000; 35: 96-103.
22. Zhang R, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 2000; 6: 393-416.
23. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
24. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
25. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375: 691-694.
26. Balint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999; 18: 3923-3929.
27. Breitfeld PP, Meyer WH. Rhabdomyosarcoma: New windows of opportunity. Oncologist 2005; 10: 518-527.
28. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639-649.
29. Garcia-Ruiz C, Mari M, Morales A, Colell A, Ardite E, Fernandez-Checa JC. Human placenta sphingomyelinase, an exogenous acidic pH-optimum sphingomyelinase, induces oxidative stress, glutathione depletion, and apoptosis in rat hepatocytes. Hepatology 2000; 32: 56-65.
30. Reed JC. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34: 9-19.
31. Kang KH, Kim WH, Choi KH. p21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp Cell Res 1999; 253: 403-412.
32. Oh WJ, Kim WH, Kang KH, Kim TY, Kim MY, Choi KH. Induction of p21 during ceramide-mediated apoptosis in human hepatocarcinoma cells. Cancer Lett 1998; 129: 215-222.
33. Alesse E, Zazzeroni F, Angelucci A, Giannini G, Di Marcotullio L, Gulino A. The growth arrest and downregulation of c-myc transcription induced by caramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering. Cell Death Differ 1998; 5: 381-389.
34. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20: 1803-1815.
35. Dash BC, El-Deiry WS. Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 2005; 25: 3364-3387.
36. Dbaibo GS, Pushkareva MY, Jayadev S, Schwarz JK, Horowitz JM, Obeid LM et al. Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. Proc Natl Acad Sci USA 1995; 92: 1347-1351.
37. Spyridopoulos I, Mayer P, Shook KS, Axel DI, Viebahn R, Karsch KR. Loss of cyclin A and G1-cell cycle arrest are a prerequisite of ceramide-induced toxicity in human arterial endothelial cells. Cardiovasc Res 2001; 50: 97-107.
38. Zhu XF, Liu ZC, Xie BF, Feng GK, Zeng YX. Ceramide induces cell cycle arrest and upregulates p27kip in nasopharyngeal carcinoma cells. Cancer Lett 2003; 193: 149-154.
39. Rani CS, Abe A, Chang Y, Rosenzweig N, Saltiel AR, Radin NS et al. Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J Biol Chem 1995; 270: 2859-2867.
40. Zhou BB, Chaturvedi P, Spring K, Scott SP, Johanson RA, Mishra R et al. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem 2000; 275: 10342-10348.
41. Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 1995; 267: 1022-1024.
42. Gartel AL, Radhakrishnan SK. Lost in transcription: P21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-3985.
43. Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H et al. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res 1987; 47: 4501-4507.
44. Phillips DC, Martin S, Doyle BT, Houghton JA. Sphingosine-induced apoptosis in rhabdomyosarcoma cell lines is dependent on pre-mitochondrial Bax activation and post-mitochondrial caspases. Cancer Res 2007; 67: 756-764.